UK Markets open in 2 hrs 32 mins

Biocartis Group NV (BCART.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
3.3800-0.1500 (-4.25%)
At close: 05:35PM CET
Sign in to post a message.
  • A
    Anonymous
    US S&P Market looks to be rolling over on China Trade concerns. As I said before, the rush to extract money from the market (IPO's, secondaries, convertibles, etc) foretold this weakness. Trump is about to learn what most the world already knew, " no-one wins a trade war". I expect that BCART will turn down in the short term as rumors are that Trump wants to renegotiate the EU trade agreements and extract Iran related concessions from the EU before the 2020 election cycle. Long term I do not expect that any of this will have a lasting effect on BCART. They are still making headway into emerging markets and China. The Wonfu agreement may even start bearing some fruit before the U.S. trade spat runs its course.

    We are very early in the MDx and CDx innovation revolution (I would not even call it a cycle since I believe it will run as long as the eye can see). BCART is situated to be a leader in the PCR IVD quick TAT part of this business the way Cepheid was in infectious diseases. Numerous NGS leaders are also emerging. There will be room for both. I do see a dilemma developing. BCART is targeting large research institutions 1st in the US. Their most natural market may be smaller to mid size hospitals and clinics looking for an economical way to incorporate MDx into their diagnostic decision making. The large institutions generally have access to faster TAT NGS profiling so their need is not as critical. Access to the smaller hospitals, clinics and labs is going to be largely contingent on insurance reimbursement. Hopefully, the JnJ collaboration in NJ and the additional funds from the convertible allow BCART to expedite the FDA approval to full diagnostic certification.

    FL
  • G
    Giloeskei
    This is just the beginning for Bcart. The Idylla platform is a hidden gem, they just needed more exposure. In these times rapid and especially accurate Poc testing are a must. Trading update provided 68% cartridge volume sale increase in Q1. Back to >10 in 2020
  • O
    OhM
    This stock could very well be a hidden gem, one to follow close...
  • A
    Anonymous
    Resolution
    I realize that nobody visits this board but thought I'd post on the off chance that someone out there is following BCART. Today we start a new Qtr, the BCART chart is at a resolution point where the long term uptrend that began in August 2016 is meeting the short term decline that started in Jan 2018. Any thoughts how this resolves?? My guess is that a catalyst such as release of MSI cartridge will be necessary to resume the climb. BCART has been touting its release this Qtr. I would hope early in the quarter since their social media campaign has ramped up the last few weeks.

    FL
  • A
    Anonymous
    The RT-qPCR-based assay, which has 510(k) clearance, is designed to rapidly differentiate sepsis from systemic inflammatory response syndrome.
    The RT-qPCR-based assay, which has 510(k) clearance, is designed to rapidly differentiate sepsis from systemic inflammatory response syndrome.
    www.genomeweb.com
  • G
    GeertH
    1Y target of 17$ at Yahoo and 8+#$%$ concensus in Europe but do not understand why this stock keeps ?underperforming?. What is going on? Not enough exposure?
  • A
    Anonymous
    Well BCART has resumed production on ML2. Hopefully it is not constrained by any reagent availability issues. I'm anxious for them to show improved margins. Right now the costs as much if not more as a percentage of revenue. They need to conclusively demonstrate that they are on the road to profitability.

    FL
  • M
    Michael
    biocartis long!!
  • t
    tobias
    Bought in today for 1000 shares , aiming for $8 long term.

    Undervalued and oversold
  • T
    Tobias
    biocartis is a serious company. production and sales are just beginning ... Vert good share for next year...
  • M
    MAURIZIO
    good company
  • D
    David
    To quadriple.... in share price within a year
  • A
    Anonymous
    China

    The China news has been in the works for a while. However, the manufacturing partner arrangement is always worrisome since the Chinese have used these types of partnerships in the past to steal intellectual property. Huge market, lots of potential but I hope BCART has IP protections.

    FL
  • S
    Sparky
    jammer
  • A
    Anonymous
    Equity Raise

    While the last conf call indicated adequate cash reserves (i.e., +-100 million Euro), I believe that BCART is still probably at least 1 more equity raise from profitability. The company should take advantage of the recent opening of the North American headquarters in New Jersey to launch an ADR on the NYSE. BCART has a great story to tell with a lot of US partners but they would benefit from the visibility of a NYSE listing.

    FL

    FL
  • A
    Anonymous
    The half year earnings call on Sept 6 coincides with world Sepsis awareness day. No finer time to announce the release of an announcement of the release of an Idylla Septicyte test. The collaboration with Immunexpress looks like it dates back to 2012 not necessarily the January press release date.

    FL
  • A
    Anonymous
    GHDX is rocketing 20% on a re-release of the Taylor X study at ASCO. I've sold out of GHDX today. If this is such good news, I'd rather own the platform that the Onco-DX test is migrating to. I believe that BCART has made the right decisions at the right time (switching emphasis from the more crowded infectious disease space, building the 2nd cartridge line to boost production, teaming w JnJ to boost new product lines, etc.) Now execution becomes the focus. They need to roll out microsatallite instability and Onco-DX in a timely manner.

    FL
  • A
    Anonymous
    Kim Popovits the CEO of GH compared BCART to Cepheid in that they have developed a product that looks likely to be positioned in many labs for MDX analysis of tumors in a similar way that cepheid equipment was positioned for infectious diseases (Refer to GHDX November presentation). Cepheid was bought out by Danaher in late 2016 after about a X10 run up.

    FL
  • A
    Anonymous
    FDA Launches Priority Review 510 Pathway
    Idylla IVD would seem like a great candidate for expedited approval. How much would ditching the RUO designation be worth in terms of console and cartridge sales? It would also allow Biocartis and their partners to distribute educational information and ads over the platform!!

    FL

    https://www.emergobyul.com/blog/2017/10/us-fda-rolls-out-new-market-pathway-breakthrough-medical-devices
    EMERGO SUMMARY OF KEY POINTS: The US FDA is launching a new expedited registration route for breakthrough and innovative medical devices. The Breakthrough Devices Program covers qualifying 510(k), Premarket Approval (PMA), Investigational Device Exem
    EMERGO SUMMARY OF KEY POINTS: The US FDA is launching a new expedited registration route for breakthrough and innovative medical devices. The Breakthrough Devices Program covers qualifying 510(k), Premarket Approval (PMA), Investigational Device Exem
    www.emergobyul.com